Amarin CorpAMRN
Market Cap: 327M
About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Employees: 275
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
199% more call options, than puts
Call options by funds: $906K | Put options by funds: $303K
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]
3.34% less ownership
Funds ownership: 24.84% [Q4 2023] → 21.51% (-3.34%) [Q1 2024]
6% less funds holding
Funds holding: 178 [Q4 2023] → 167 (-11) [Q1 2024]
8% less capital invested
Capital invested by funds: $85.8M [Q4 2023] → $78.7M (-$7.12M) [Q1 2024]
38% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 29
Research analyst outlook
We haven’t received any recent analyst ratings for AMRN.
Financial journalist opinion
Based on 3 articles about AMRN published over the past 30 days